FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1116627558> ?p ?o ?g. }

• W1116627558 endingPage "777" @default.
• W1116627558 startingPage "771" @default.
• W1116627558 abstract "This study estimated the cost-effectiveness of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) when used in first-line acute promyelocytic leukemia (APL) treatment.A Markov cohort model was developed with 3 states: stable disease (during first- or second-line treatment), disease event, and death. Newly diagnosed patients with low- to intermediate-risk APL were included and each month could remain in their current health state or move to another. Treatment consisted of ATO + ATRA, ATRA + idarubicin (IDA), or ATRA + cytarabine (AraC) + additional chemotherapy. After an initial disease event, patients discontinued first-line therapy and switched to a second-line ATO regimen. Efficacy and safety data were obtained from published trials; quality of life/utility estimates were obtained from the literature; costs were obtained from US data sources. Costs and outcomes over time were used to calculate incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses were conducted.Compared to ATRA + AraC + additional chemotherapy, ATRA + IDA treatment had ICERs of $2933 per life-year (LY) saved and $3122 per quality-adjusted life-year (QALY) gained. Compared to the ATRA + IDA regimen, first-line ATO + ATRA treatment had ICERs of $4512 per LY saved and $5614 per QALY gained. Results were sensitive to changes in pharmacy costs of the ATO + ATRA regimen during consolidation.The ATO + ATRA regimen is highly cost-effective compared to ATRA + AraC + additional chemotherapy or ATRA + IDA in the treatment of newly diagnosed low- to intermediate-risk APL patients." @default.
• W1116627558 created "2016-06-24" @default.
• W1116627558 creator A5001124933 @default.
• W1116627558 creator A5025976409 @default.
• W1116627558 creator A5030214706 @default.
• W1116627558 creator A5048205061 @default.
• W1116627558 creator A5063111161 @default.
• W1116627558 creator A5084859825 @default.
• W1116627558 creator A5085436731 @default.
• W1116627558 creator A5086382821 @default.
• W1116627558 date "2015-12-01" @default.
• W1116627558 modified "2023-09-27" @default.
• W1116627558 title "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States" @default.
• W1116627558 cites W1931891535 @default.
• W1116627558 cites W1965141571 @default.
• W1116627558 cites W1979871017 @default.
• W1116627558 cites W1992276338 @default.
• W1116627558 cites W1992842669 @default.
• W1116627558 cites W1996652585 @default.
• W1116627558 cites W2003474867 @default.
• W1116627558 cites W2019187521 @default.
• W1116627558 cites W2045926255 @default.
• W1116627558 cites W2046339855 @default.
• W1116627558 cites W2046705094 @default.
• W1116627558 cites W2057205771 @default.
• W1116627558 cites W2058056848 @default.
• W1116627558 cites W2066421899 @default.
• W1116627558 cites W2070487839 @default.
• W1116627558 cites W2071930065 @default.
• W1116627558 cites W2084219839 @default.
• W1116627558 cites W2089988981 @default.
• W1116627558 cites W2103323412 @default.
• W1116627558 cites W2107753068 @default.
• W1116627558 cites W2113761338 @default.
• W1116627558 cites W2128291738 @default.
• W1116627558 cites W2129338773 @default.
• W1116627558 cites W2138630072 @default.
• W1116627558 cites W2143075695 @default.
• W1116627558 cites W2149576798 @default.
• W1116627558 cites W2151347057 @default.
• W1116627558 cites W2154884497 @default.
• W1116627558 cites W2156005373 @default.
• W1116627558 cites W2159973719 @default.
• W1116627558 cites W2170332354 @default.
• W1116627558 cites W2314037093 @default.
• W1116627558 doi "https://doi.org/10.1016/j.clml.2015.07.634" @default.
• W1116627558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5028894" @default.
• W1116627558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26361645" @default.
• W1116627558 hasPublicationYear "2015" @default.
• W1116627558 type Work @default.
• W1116627558 sameAs 1116627558 @default.
• W1116627558 citedByCount "20" @default.
• W1116627558 countsByYear W11166275582014 @default.
• W1116627558 countsByYear W11166275582016 @default.
• W1116627558 countsByYear W11166275582017 @default.
• W1116627558 countsByYear W11166275582019 @default.
• W1116627558 countsByYear W11166275582020 @default.
• W1116627558 countsByYear W11166275582021 @default.
• W1116627558 countsByYear W11166275582022 @default.
• W1116627558 countsByYear W11166275582023 @default.
• W1116627558 crossrefType "journal-article" @default.
• W1116627558 hasAuthorship W1116627558A5001124933 @default.
• W1116627558 hasAuthorship W1116627558A5025976409 @default.
• W1116627558 hasAuthorship W1116627558A5030214706 @default.
• W1116627558 hasAuthorship W1116627558A5048205061 @default.
• W1116627558 hasAuthorship W1116627558A5063111161 @default.
• W1116627558 hasAuthorship W1116627558A5084859825 @default.
• W1116627558 hasAuthorship W1116627558A5085436731 @default.
• W1116627558 hasAuthorship W1116627558A5086382821 @default.
• W1116627558 hasBestOaLocation W11166275582 @default.
• W1116627558 hasConcept C104317684 @default.
• W1116627558 hasConcept C112930515 @default.
• W1116627558 hasConcept C126322002 @default.
• W1116627558 hasConcept C143998085 @default.
• W1116627558 hasConcept C185592680 @default.
• W1116627558 hasConcept C190283241 @default.
• W1116627558 hasConcept C2776601000 @default.
• W1116627558 hasConcept C2776694085 @default.
• W1116627558 hasConcept C2778041864 @default.
• W1116627558 hasConcept C2780386689 @default.
• W1116627558 hasConcept C2781121885 @default.
• W1116627558 hasConcept C2781413609 @default.
• W1116627558 hasConcept C3019080777 @default.
• W1116627558 hasConcept C515549039 @default.
• W1116627558 hasConcept C55493867 @default.
• W1116627558 hasConcept C64332521 @default.
• W1116627558 hasConcept C71924100 @default.
• W1116627558 hasConceptScore W1116627558C104317684 @default.
• W1116627558 hasConceptScore W1116627558C112930515 @default.
• W1116627558 hasConceptScore W1116627558C126322002 @default.
• W1116627558 hasConceptScore W1116627558C143998085 @default.
• W1116627558 hasConceptScore W1116627558C185592680 @default.
• W1116627558 hasConceptScore W1116627558C190283241 @default.
• W1116627558 hasConceptScore W1116627558C2776601000 @default.
• W1116627558 hasConceptScore W1116627558C2776694085 @default.
• W1116627558 hasConceptScore W1116627558C2778041864 @default.
• W1116627558 hasConceptScore W1116627558C2780386689 @default.
• W1116627558 hasConceptScore W1116627558C2781121885 @default.

• next